- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01863225
Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
May 8, 2015 updated by: Resverlogix Corp
A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia
This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital / CMAX
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients ≥ 18 to ≤ 65 years of age with or without documented coronary artery disease.
- Taking statin therapy for at least 30 days prior to Screening (Visit 1).
- In the opinion of the investigator, patient currently on statin therapy other than atorvastatin 40 mg or rosuvastatin 20 mg or atorvastatin 80 mg or rosuvastatin 40 mg who could be switched to one of these regimens at Visit 1 for the duration of the study.
Exclusion Criteria:
- Clinically significant heart disease which will require coronary bypass, PCI, cardiac transplantation, surgical repair and/or replacement during the course of the study.
- Coronary artery bypass graft (CABG) procedure within the past 90 days.
- Have a body mass index (BMI) greater than 36 kg/m2.
- Patients of East Asian descent (due to pharmacological food effect noted for rosuvastatin).
- Previous or current diagnosis of severe heart failure (NYHA Class III-IV) or a documented left ventricular ejection fraction (LVEF) of < 25% as determined by contrast left ventriculography, radionuclide ventriculography or echocardiography. The absence of an LVEF measurement in a patient without a previous or current diagnosis of heart failure does not prohibit entry into the study.
- Patients with evidence of cardiac electrophysiologic instability including a history of uncontrolled ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response heart rate of > 100 beats per minute at rest within 4 weeks prior to Visit 1.
- Evidence of renal impairment
- Have hypertension that is uncontrolled defined as 2 consecutive measurements of sitting blood pressure of systolic >160 mmHg or diastolic > 95 mmHg at Visit 1.
- Women of child-bearing potential who do not agree to use two reliable methods of birth control during the study and for one month following the last dose of study drug, or pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive ß-hCG laboratory test (≥ 5 IU/L) at the time of enrollment. Where women of child-bearing potential are defined as women not surgically sterilized and between menarche and 1 year post menopause, and a reliable method of birth control includes use of oral contraceptives or levonorgestrel; or a reliable barrier method of birth control (diaphragms; cervical caps; condoms; intrauterine devices; partner with vasectomy; or abstinence).
- Current or recent (within 12 month prior to Visit 1) treatment with immunosuppressants (e.g., Cyclosporine).
- Triglycerides > 4.5 mmol/L at screening Visit 1.
- Use of fibrates of any dose or niacin/nicotinic acid 250 mg or more within 90 days prior to Visit 1
- Any medical or surgical condition which might significantly alter the absorption, distribution, metabolism or excretion of medication including, but not limited to any of the following: cholecystitis, Crohn's disease, ulcerative colitis, or any gastric bypass alteration.
- Evidence of hepatic disease
- A total bilirubin that is > ULN by local laboratory at screening, Visit 1
- History of malignancy of any organ system, treated or untreated, within the past 5 years of Visit 1 whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
- History or evidence of drug or alcohol abuse within 12 months of Visit 1.
- Current dependence on nicotine containing products.
- Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
- Use of any HIV and/or chemotherapy drugs, and/or antibiotics within 30 days or 5 half-lives of Visit 2, whichever is longer.
- Use of other investigational drugs and devices at the time of enrollment, or within 30 days or 5 half-lives of Visit 2, whichever is longer.
- History of noncompliance to medical regimens or unwillingness to comply with the study protocol.
- Any condition that in the opinion of the investigator would confound the evaluation and interpretation of efficacy and/or safety data.
- Persons directly involved in the execution of this protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A
RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
|
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Other Names:
40 mg daily, 28-42 days
80 mg daily, 28-42 days
|
EXPERIMENTAL: Group B
RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
|
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Other Names:
20 mg daily, 28-42 days
40 mg daily, 28-42 days
|
EXPERIMENTAL: Group C
RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
|
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Other Names:
40 mg daily, 28-42 days
80 mg daily, 28-42 days
|
EXPERIMENTAL: Group D
RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
|
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Other Names:
20 mg daily, 28-42 days
40 mg daily, 28-42 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of the pharmacokinetics of RVX000222 capsule formulation in combination with either atorvastatin or rosuvastatin in patients with dyslipidemia.
Time Frame: 14 days
|
The plasma concentration-time profile of RVX000222 capsule formulation and its metabolites on Days 1 and 14 of 200 mg daily RVX000222 in combination with either atorvastatin or rosuvastatin, including pharmacokinetic parameters Cmax, Tmax, Cmin, AUC0-12, AUC12-24, AUC0 24, and metabolite ratio.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of the pharmacokinetics of atorvastatin and rosuvastatin when either is administered in combination with RVX000222 capsule formulation to patients with dyslipidemia.
Time Frame: 14 days
|
The plasma concentration-time profile of either atorvastatin and metabolites or rosuvastatin and metabolites on Days -1 and 14 of 200 mg daily RVX000222 in combination with the statin, including pharmacokinetic parameters Cmax, Tmax, Cmin, AUC0-12, AUC12-24, AUC0 24, and metabolite ratio.
|
14 days
|
Evaluation of safety and tolerability of RVX000222 capsule formulation administered in combination with stable doses of either atorvastatin or rosuvastatin in patients with dyslipidemia.
Time Frame: 14
|
Adverse events, serious adverse events, vital signs, clinical chemistry and haematological variables will be collected and summarized across treatment groups.
|
14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr. Sepehr Shakib, Royal Adelaide Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (ACTUAL)
June 1, 2013
Study Completion (ACTUAL)
June 1, 2013
Study Registration Dates
First Submitted
May 16, 2013
First Submitted That Met QC Criteria
May 22, 2013
First Posted (ESTIMATE)
May 27, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
May 12, 2015
Last Update Submitted That Met QC Criteria
May 8, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Lipid Metabolism Disorders
- Coronary Artery Disease
- Dyslipidemias
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
- Rosuvastatin Calcium
Other Study ID Numbers
- RVX222-CS-009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on RVX000222
-
Resverlogix CorpThe Cleveland ClinicCompletedCoronary Artery DiseaseNetherlands, Spain, Russian Federation, Belgium, Brazil, Argentina, Poland, Hungary
-
Resverlogix CorpNucleus Network Ltd; Baker Heart and Diabetes InstituteCompleted
-
Resverlogix CorpThe Cleveland ClinicCompletedCoronary Artery Disease | DyslipidemiaSouth Africa
-
Resverlogix CorpWithdrawn
-
Resverlogix CorpCompletedSafety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL CholesterolCardiovascular Disease | Atherosclerosis | Dyslipidemia | Acute Coronary SyndromeUnited States
-
Resverlogix CorpCompletedCoronary Artery Disease | AtherosclerosisUnited States
-
Resverlogix CorpNot yet recruiting
-
Resverlogix CorpPPD; ICON plc; Medidata SolutionsCompletedCoronary Artery Disease | Diabetes Mellitus, Type 2Netherlands, Taiwan, Argentina, Israel, Poland, Russian Federation, Australia, Belgium, Serbia, Bulgaria, Hungary, Slovakia, Mexico, Croatia, Germany